A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma

Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Keun-Wook, Yun, Tak, Song, Eun Kee, Na, Im il, Shin, Hyunchoon, Bang, Soo-Mee, Lee, Jae Hoon, Lee, Seung Tae, Kim, Jee Hyun, Yoon, Sung-Soo, Lee, Jong Seok, Park, Seonyang, Kim, Byoung Kook, Kim, Noe Kyeong
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2005
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782154/
https://www.ncbi.nlm.nih.gov/pubmed/16100450
http://dx.doi.org/10.3346/jkms.2005.20.4.598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782154/
https://www.ncbi.nlm.nih.gov/pubmed/16100450
http://dx.doi.org/10.3346/jkms.2005.20.4.598

Ejemplares similares